JP2010526868A - 改変されたエフェクター機能を有するFc受容体結合ポリペプチド - Google Patents
改変されたエフェクター機能を有するFc受容体結合ポリペプチド Download PDFInfo
- Publication number
- JP2010526868A JP2010526868A JP2010508009A JP2010508009A JP2010526868A JP 2010526868 A JP2010526868 A JP 2010526868A JP 2010508009 A JP2010508009 A JP 2010508009A JP 2010508009 A JP2010508009 A JP 2010508009A JP 2010526868 A JP2010526868 A JP 2010526868A
- Authority
- JP
- Japan
- Prior art keywords
- amino acid
- antibody
- modified
- human
- antibodies
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Withdrawn
Links
Images
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/06—Anti-spasmodics, e.g. drugs for colics, esophagic dyskinesia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/10—Laxatives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/12—Antidiarrhoeals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2896—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against molecules with a "CD"-designation, not provided for elsewhere
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/52—Constant or Fc region; Isotype
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/71—Decreased effector function due to an Fc-modification
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Immunology (AREA)
- Pulmonology (AREA)
- Biochemistry (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Molecular Biology (AREA)
- Genetics & Genomics (AREA)
- Biophysics (AREA)
- Rheumatology (AREA)
- Heart & Thoracic Surgery (AREA)
- Pain & Pain Management (AREA)
- Vascular Medicine (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Physical Education & Sports Medicine (AREA)
- Diabetes (AREA)
- Hematology (AREA)
- Transplantation (AREA)
- Cardiology (AREA)
- Urology & Nephrology (AREA)
- Peptides Or Proteins (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US93027607P | 2007-05-14 | 2007-05-14 | |
PCT/IB2008/003978 WO2009101479A2 (en) | 2007-05-14 | 2008-05-14 | Fc receptor-binding polypeptides with modified effector functions |
Related Child Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2013213487A Division JP2014005306A (ja) | 2007-05-14 | 2013-10-11 | 改変されたエフェクター機能を有するFc受容体結合ポリペプチド |
Publications (1)
Publication Number | Publication Date |
---|---|
JP2010526868A true JP2010526868A (ja) | 2010-08-05 |
Family
ID=40957323
Family Applications (6)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2010508009A Withdrawn JP2010526868A (ja) | 2007-05-14 | 2008-05-14 | 改変されたエフェクター機能を有するFc受容体結合ポリペプチド |
JP2013213487A Withdrawn JP2014005306A (ja) | 2007-05-14 | 2013-10-11 | 改変されたエフェクター機能を有するFc受容体結合ポリペプチド |
JP2014218179A Withdrawn JP2015017133A (ja) | 2007-05-14 | 2014-10-27 | 改変されたエフェクター機能を有するFc受容体結合ポリペプチド |
JP2016221204A Active JP6360128B2 (ja) | 2007-05-14 | 2016-11-14 | 改変されたエフェクター機能を有するFc受容体結合ポリペプチド |
JP2018028606A Withdrawn JP2018087234A (ja) | 2007-05-14 | 2018-02-21 | 改変されたエフェクター機能を有するFc受容体結合ポリペプチド |
JP2020074563A Pending JP2020111613A (ja) | 2007-05-14 | 2020-04-20 | 改変されたエフェクター機能を有するFc受容体結合ポリペプチド |
Family Applications After (5)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2013213487A Withdrawn JP2014005306A (ja) | 2007-05-14 | 2013-10-11 | 改変されたエフェクター機能を有するFc受容体結合ポリペプチド |
JP2014218179A Withdrawn JP2015017133A (ja) | 2007-05-14 | 2014-10-27 | 改変されたエフェクター機能を有するFc受容体結合ポリペプチド |
JP2016221204A Active JP6360128B2 (ja) | 2007-05-14 | 2016-11-14 | 改変されたエフェクター機能を有するFc受容体結合ポリペプチド |
JP2018028606A Withdrawn JP2018087234A (ja) | 2007-05-14 | 2018-02-21 | 改変されたエフェクター機能を有するFc受容体結合ポリペプチド |
JP2020074563A Pending JP2020111613A (ja) | 2007-05-14 | 2020-04-20 | 改変されたエフェクター機能を有するFc受容体結合ポリペプチド |
Country Status (14)
Country | Link |
---|---|
US (3) | US8546539B2 (he) |
EP (1) | EP2173381B1 (he) |
JP (6) | JP2010526868A (he) |
CN (1) | CN101720232B (he) |
AU (1) | AU2008350535B2 (he) |
CA (1) | CA2689680C (he) |
DK (1) | DK2173381T3 (he) |
ES (1) | ES2441189T3 (he) |
IL (1) | IL202107A (he) |
MX (1) | MX2009012319A (he) |
PL (1) | PL2173381T3 (he) |
PT (1) | PT2173381E (he) |
SI (1) | SI2173381T1 (he) |
WO (1) | WO2009101479A2 (he) |
Cited By (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2014505056A (ja) * | 2011-01-10 | 2014-02-27 | ノビミューン エスアー | 抗tlr4抗体およびその使用法 |
JP2015514094A (ja) * | 2012-03-29 | 2015-05-18 | ノビミューン エスアー | 抗tlr4抗体およびその使用 |
JP2018523827A (ja) * | 2015-08-06 | 2018-08-23 | ノビミューン エスアー | Tlr4依存性障害の診断および処置のための患者集団を特定するための方法および組成物 |
Families Citing this family (12)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
PT2173381E (pt) * | 2007-05-14 | 2013-12-13 | Novimmune Sa | Polipéptidos que se ligam ao receptor fc, com funções efectivadoras modificadas |
IE20090514A1 (en) * | 2009-07-06 | 2011-02-16 | Opsona Therapeutics Ltd | Humanised antibodies and uses therof |
AU2014338991B2 (en) * | 2013-10-22 | 2020-06-11 | Novimmune S.A. | Methods and compositions for diagnosis and treatment of disorders in patients with elevated levels of TLR4 ligands and other biomarkers |
WO2015082716A1 (en) | 2013-12-06 | 2015-06-11 | Novimmune S.A. | Anti-tlr4 antibodies and methods of use thereof |
AU2018244574A1 (en) * | 2017-03-28 | 2019-10-31 | Lyvgen Biopharma Holdings Limited | Therapeutic agents and methods for enhancing immune responses in tumor microenvironment |
US11623963B2 (en) * | 2017-10-03 | 2023-04-11 | Merck Patent Gmbh | Cysteine engineered antigen-binding molecules |
AR122263A1 (es) * | 2019-05-09 | 2022-08-31 | Genentech Inc | Métodos para producir anticuerpos |
KR20220129026A (ko) * | 2020-01-17 | 2022-09-22 | 유니버시티 오브 테네시 리서치 파운데이션 | 아밀로이드 제거를 위한 키메라 항원 수용체 |
CN115697410A (zh) * | 2020-04-20 | 2023-02-03 | 艾德沙生物科技研究公司 | 用于治疗急性呼吸窘迫综合征的组合物和方法 |
EP4204003A1 (en) * | 2020-08-28 | 2023-07-05 | Board of Regents, The University of Texas System | Antibodies specific to ccl21 and methods of use |
WO2024040115A2 (en) * | 2022-08-16 | 2024-02-22 | University Of Vermont And State Agricultural College | ANTIBODIES FOR PLATELET FCγRIIA AND RELATED METHODS OF USE |
WO2024040195A1 (en) | 2022-08-17 | 2024-02-22 | Capstan Therapeutics, Inc. | Conditioning for in vivo immune cell engineering |
Citations (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2005065015A2 (en) * | 2003-12-10 | 2005-07-21 | Novimmune Sa | Neutralizing antibodies and methods of use thereof |
US20060134709A1 (en) * | 2004-11-10 | 2006-06-22 | Jeffery Stavenhagen | Engineering Fc antibody regions to confer effector function |
WO2006077471A2 (en) * | 2004-12-10 | 2006-07-27 | Novimmune S.A. | Combining therapies targeting multiple toll-like receptors and use thereof |
WO2006085967A2 (en) * | 2004-07-09 | 2006-08-17 | Xencor, Inc. | OPTIMIZED ANTI-CD20 MONOCONAL ANTIBODIES HAVING Fc VARIANTS |
Family Cites Families (29)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US993904A (en) | 1911-02-28 | 1911-05-30 | Ribbon Metals Syndicate Ltd | Apparatus for making metal strips, foil, sheets, or ribbons. |
FR2413974A1 (fr) | 1978-01-06 | 1979-08-03 | David Bernard | Sechoir pour feuilles imprimees par serigraphie |
US4485045A (en) | 1981-07-06 | 1984-11-27 | Research Corporation | Synthetic phosphatidyl cholines useful in forming liposomes |
US4522811A (en) | 1982-07-08 | 1985-06-11 | Syntex (U.S.A.) Inc. | Serial injection of muramyldipeptides and liposomes enhances the anti-infective activity of muramyldipeptides |
US4816567A (en) | 1983-04-08 | 1989-03-28 | Genentech, Inc. | Recombinant immunoglobin preparations |
US4544545A (en) | 1983-06-20 | 1985-10-01 | Trustees University Of Massachusetts | Liposomes containing modified cholesterol for organ targeting |
US4676980A (en) | 1985-09-23 | 1987-06-30 | The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services | Target specific cross-linked heteroantibodies |
DE3788058T2 (de) | 1986-08-28 | 1994-04-21 | Teijin Ltd | Zelltoxischer antikörperkomplex und verfahren zu seiner herstellung. |
ES2096590T3 (es) | 1989-06-29 | 1997-03-16 | Medarex Inc | Reactivos biespecificos para la terapia del sida. |
US5013556A (en) | 1989-10-20 | 1991-05-07 | Liposome Technology, Inc. | Liposomes with enhanced circulation time |
CA2102511A1 (en) | 1991-05-14 | 1992-11-15 | Paul J. Higgins | Heteroconjugate antibodies for treatment of hiv infection |
DK0669836T3 (da) | 1992-11-13 | 1996-10-14 | Idec Pharma Corp | Terapeutisk anvendelse af kimære og radioaktivt mærkede antistoffer og humant B-lymfocytbegrænset differentieringsantigen til behandling af B-cellelymfom |
JPH08510909A (ja) | 1993-05-28 | 1996-11-19 | ザ スクリップス リサーチ インスティチュート | Cd14媒介細胞活性化を抑制するための方法および組成物 |
US6528624B1 (en) | 1998-04-02 | 2003-03-04 | Genentech, Inc. | Polypeptide variants |
ES2532910T3 (es) | 1998-04-02 | 2015-04-01 | Genentech, Inc. | Variantes de anticuerpos y fragmentos de los mismos |
EP1746107B1 (en) | 1998-04-02 | 2014-12-17 | Genentech, Inc. | Antibody variants and fragments thereof |
ES2694002T3 (es) | 1999-01-15 | 2018-12-17 | Genentech, Inc. | Polipéptido que comprende una región Fc de IgG1 humana variante |
US6737056B1 (en) | 1999-01-15 | 2004-05-18 | Genentech, Inc. | Polypeptide variants with altered effector function |
US20040132101A1 (en) * | 2002-09-27 | 2004-07-08 | Xencor | Optimized Fc variants and methods for their generation |
AU2003217912A1 (en) * | 2002-03-01 | 2003-09-16 | Xencor | Antibody optimization |
US8093357B2 (en) * | 2002-03-01 | 2012-01-10 | Xencor, Inc. | Optimized Fc variants and methods for their generation |
US8188231B2 (en) | 2002-09-27 | 2012-05-29 | Xencor, Inc. | Optimized FC variants |
ATE510853T1 (de) | 2003-09-23 | 2011-06-15 | Univ Muenchen Tech | Tlr2-antagonistischer antikörper und dessen verwendung |
US7312320B2 (en) * | 2003-12-10 | 2007-12-25 | Novimmune Sa | Neutralizing antibodies and methods of use thereof |
US7674884B2 (en) | 2003-12-10 | 2010-03-09 | Novimmune S.A. | Neutralizing antibodies and methods of use thereof |
CA2602663A1 (en) | 2005-03-31 | 2006-10-05 | Xencor, Inc. | Fc variants with optimized properties |
PT2173381E (pt) * | 2007-05-14 | 2013-12-13 | Novimmune Sa | Polipéptidos que se ligam ao receptor fc, com funções efectivadoras modificadas |
WO2012096917A1 (en) * | 2011-01-10 | 2012-07-19 | Novimmune S.A. | Anti-tlr4 antibodies and methods of use thereof |
PL2831117T3 (pl) * | 2012-03-29 | 2018-03-30 | Novimmune Sa | Przeciwciała anty-TLR4 i ich zastosowania |
-
2008
- 2008-05-14 PT PT88724679T patent/PT2173381E/pt unknown
- 2008-05-14 CN CN200880021687XA patent/CN101720232B/zh active Active
- 2008-05-14 EP EP08872467.9A patent/EP2173381B1/en active Active
- 2008-05-14 ES ES08872467.9T patent/ES2441189T3/es active Active
- 2008-05-14 JP JP2010508009A patent/JP2010526868A/ja not_active Withdrawn
- 2008-05-14 SI SI200831114T patent/SI2173381T1/sl unknown
- 2008-05-14 PL PL08872467T patent/PL2173381T3/pl unknown
- 2008-05-14 MX MX2009012319A patent/MX2009012319A/es active IP Right Grant
- 2008-05-14 WO PCT/IB2008/003978 patent/WO2009101479A2/en active Application Filing
- 2008-05-14 DK DK08872467.9T patent/DK2173381T3/da active
- 2008-05-14 CA CA2689680A patent/CA2689680C/en active Active
- 2008-05-14 US US12/152,395 patent/US8546539B2/en active Active
- 2008-05-14 AU AU2008350535A patent/AU2008350535B2/en active Active
-
2009
- 2009-11-12 IL IL202107A patent/IL202107A/he active IP Right Grant
-
2013
- 2013-10-01 US US14/043,071 patent/US9688755B2/en active Active
- 2013-10-11 JP JP2013213487A patent/JP2014005306A/ja not_active Withdrawn
-
2014
- 2014-10-27 JP JP2014218179A patent/JP2015017133A/ja not_active Withdrawn
-
2016
- 2016-11-14 JP JP2016221204A patent/JP6360128B2/ja active Active
-
2017
- 2017-06-26 US US15/632,961 patent/US20170298129A1/en not_active Abandoned
-
2018
- 2018-02-21 JP JP2018028606A patent/JP2018087234A/ja not_active Withdrawn
-
2020
- 2020-04-20 JP JP2020074563A patent/JP2020111613A/ja active Pending
Patent Citations (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2005065015A2 (en) * | 2003-12-10 | 2005-07-21 | Novimmune Sa | Neutralizing antibodies and methods of use thereof |
WO2006085967A2 (en) * | 2004-07-09 | 2006-08-17 | Xencor, Inc. | OPTIMIZED ANTI-CD20 MONOCONAL ANTIBODIES HAVING Fc VARIANTS |
US20060134709A1 (en) * | 2004-11-10 | 2006-06-22 | Jeffery Stavenhagen | Engineering Fc antibody regions to confer effector function |
WO2006077471A2 (en) * | 2004-12-10 | 2006-07-27 | Novimmune S.A. | Combining therapies targeting multiple toll-like receptors and use thereof |
Cited By (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2014505056A (ja) * | 2011-01-10 | 2014-02-27 | ノビミューン エスアー | 抗tlr4抗体およびその使用法 |
JP2017137319A (ja) * | 2011-01-10 | 2017-08-10 | ノビミューン エスアー | 抗tlr4抗体およびその使用法 |
JP2015514094A (ja) * | 2012-03-29 | 2015-05-18 | ノビミューン エスアー | 抗tlr4抗体およびその使用 |
JP2018523827A (ja) * | 2015-08-06 | 2018-08-23 | ノビミューン エスアー | Tlr4依存性障害の診断および処置のための患者集団を特定するための方法および組成物 |
Also Published As
Publication number | Publication date |
---|---|
JP2018087234A (ja) | 2018-06-07 |
PT2173381E (pt) | 2013-12-13 |
CA2689680A1 (en) | 2009-08-20 |
IL202107A0 (en) | 2011-08-01 |
US8546539B2 (en) | 2013-10-01 |
US20120142098A1 (en) | 2012-06-07 |
DK2173381T3 (da) | 2013-12-02 |
EP2173381A2 (en) | 2010-04-14 |
EP2173381B1 (en) | 2013-10-02 |
JP2014005306A (ja) | 2014-01-16 |
US9688755B2 (en) | 2017-06-27 |
WO2009101479A2 (en) | 2009-08-20 |
US20140038287A1 (en) | 2014-02-06 |
JP2020111613A (ja) | 2020-07-27 |
MX2009012319A (es) | 2010-03-01 |
JP2015017133A (ja) | 2015-01-29 |
AU2008350535A1 (en) | 2009-08-20 |
WO2009101479A3 (en) | 2010-02-25 |
US20170298129A1 (en) | 2017-10-19 |
CN101720232A (zh) | 2010-06-02 |
PL2173381T3 (pl) | 2014-03-31 |
JP6360128B2 (ja) | 2018-07-18 |
IL202107A (he) | 2014-05-28 |
AU2008350535B2 (en) | 2013-08-22 |
CA2689680C (en) | 2017-11-07 |
JP2017036333A (ja) | 2017-02-16 |
CN101720232B (zh) | 2013-07-10 |
SI2173381T1 (sl) | 2014-01-31 |
ES2441189T3 (es) | 2014-02-03 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
JP6360128B2 (ja) | 改変されたエフェクター機能を有するFc受容体結合ポリペプチド | |
US10982004B2 (en) | Anti-TLR4 antibodies and uses thereof | |
JP6392770B2 (ja) | 抗cd47抗体およびその使用方法 | |
JP2014005301A (ja) | 中和抗体およびその使用方法 | |
US20180142018A1 (en) | Anti-cd19 antibodies and methods of use thereof | |
WO2022200389A1 (en) | Bispecific antibodies targeting cd47 and pd-l1 and methods of use thereof |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
A621 | Written request for application examination |
Free format text: JAPANESE INTERMEDIATE CODE: A621 Effective date: 20110511 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20120501 |
|
A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20130415 |
|
A601 | Written request for extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A601 Effective date: 20130712 |
|
A602 | Written permission of extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A602 Effective date: 20130722 |
|
A601 | Written request for extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A601 Effective date: 20130813 |
|
A602 | Written permission of extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A602 Effective date: 20130820 |
|
A601 | Written request for extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A601 Effective date: 20130913 |
|
A602 | Written permission of extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A602 Effective date: 20130924 |
|
A02 | Decision of refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A02 Effective date: 20131204 |
|
A761 | Written withdrawal of application |
Free format text: JAPANESE INTERMEDIATE CODE: A761 Effective date: 20131206 |